Insider · CIK 0001647647
Barbara Klencke
directorofficer
Files at XNCR (Xencor Inc), TCRX (TScan Therapeutics, Inc.), ALXO (ALX ONCOLOGY HOLDINGS INC). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Stock option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Apr 17, 2026 |
| Mar 3, 2026 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Stock option (right to buy)derivative | +700,000 | $0.00 | $0 | 700,000 | Mar 5, 2026 |
| Sep 17, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Stock option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Sep 19, 2025 |
| Jun 30, 2025 | TCRX TScan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +67,000 | $0.00 | $0 | 67,000 | Jul 2, 2025 |
| Jun 12, 2025 | XNCR Xencor Inc | AGrant or award Common Stock | +13,686 | $0.00 | $0 | 19,672 | Jun 16, 2025 |
| Jun 12, 2025 | XNCR Xencor Inc | AGrant or award Stock Option (Right to Buy)derivative | +27,372 | $0.00 | $0 | 27,372 | Jun 16, 2025 |
| Jan 21, 2025 | ALXO ALX ONCOLOGY HOLDINGS INC | AGrant or award Stock Option (right to buy)derivative | +40,400 | $0.00 | $0 | 40,400 | Jan 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.